1. Introduction {#sec1-ijms-19-02100}
===============

Bioactive peptides, as functional ingredients and pharmaceutical agents, have attracted much more attention in recent years \[[@B1-ijms-19-02100],[@B2-ijms-19-02100],[@B3-ijms-19-02100]\]. With the development of new isolation and identification technologies, the study of the relationship of sequence and structure of bioactive peptides has rapidly evolved \[[@B3-ijms-19-02100],[@B4-ijms-19-02100]\].

*Mytilus edulis* is a typical marine bivalve mollusk. Many kinds of nutritional and pharmaceutical benefits of *Mytilus edulis* have been reported, such as nourishing the liver and kidneys, adjusting blood pressure, curing night sweats, dizziness and impotence, and so on \[[@B5-ijms-19-02100]\]. More and more bioactive peptides from the *M. edulis* whole body rather than different tissues, such as antimicrobial peptides \[[@B6-ijms-19-02100],[@B7-ijms-19-02100]\], anti-inflammatory peptides \[[@B5-ijms-19-02100]\], antioxidant peptides \[[@B8-ijms-19-02100],[@B9-ijms-19-02100]\] and anticoagulant peptides, have been reported in recent years. Meanwhile, the bioactive peptides from different tissues of *M. edulis* are identifiable \[[@B10-ijms-19-02100]\].

Thrombosis may cause serious complications such as an increase in portal venous pressure and an intestinal infarction. Previous surveys have indicated that the majority of serious diseases are thrombotic diseases, which may result in sudden death or long-term disability \[[@B11-ijms-19-02100]\]. In recent years, bioactive peptides have received increasing attention. Similarly, there is an increasing need for anticoagulant and antithrombotic peptides to cure thrombosis. In these booming fields, those natural peptides with thrombin-inhibitory activity have attracted much more attention and have been evaluated extensively. Therefore, it is necessary to elaborate the preparation methods of target peptides. Indeed, blood clotting is a complicated physiological process controlled by a series of proteolytic reactions with comprehensive interactions \[[@B12-ijms-19-02100],[@B13-ijms-19-02100]\]. The blood coagulation pathway involves the interaction of many plasma serine proteases known as blood clotting factors \[[@B5-ijms-19-02100]\]. Therefore, the molecular mechanism of protein/peptide recognition has very important implications in the fields of biology, medicine, and pharmaceutical sciences \[[@B14-ijms-19-02100]\]. Molecular docking technology has been widely used in this field in recent years \[[@B15-ijms-19-02100],[@B16-ijms-19-02100],[@B17-ijms-19-02100]\].

The antithrombotic activity of *M. edulis* hydrolysate has been reported in several studies \[[@B6-ijms-19-02100]\]. However, anticoagulant peptides were rarely isolated from *M. edulis*, and interactions between the peptide and thrombin have not been reported. The aim of this work was to prepare bioactive peptides from different tissues of *M. edulis* by trypsin digestion, and several possible anticoagulant peptides were evaluated by molecular docking and Peptide Ranker.

2. Results and Discussion {#sec2-ijms-19-02100}
=========================

2.1. Distribution of Proteins from Different Tissues {#sec2dot1-ijms-19-02100}
----------------------------------------------------

The protein content of the different samples was shown in [Figure 1](#ijms-19-02100-f001){ref-type="fig"}. The adductor muscle, foot, pedal retractor muscle, byssus, gill, mantle, other parts, and viscera were sorted depending on the protein content. The protein content of the powder of S0 was 68%. S1, S2, S3, S4, S6, S7, and S8 had significant differences compared with S0. S6 was significantly higher than S0. S2, S4, and S8 were significantly lower than S0. When the total tissue was considered to be 100%, the dry weight of the different tissues will be 65.08 ± 0.71, 71.13 ± 1.62, 68.14 ± 0.48, 69.92 ± 1, 59.25 ± 0.83, 63.41 ± 0.23, 79.22 ± 0, 51.84 ± 0.25, 58.73 ± 0.72 percent, respectively.

As shown in [Figure 2](#ijms-19-02100-f002){ref-type="fig"}, the proteins of byssus, viscera, and others about 40 kDa proteins were more noticeable than other samples. Dissolved protein concentrations were 7.45 ± 0.11, 4.53 ± 0.21, 2.88 ± 0.28, 5.71 ± 0.05, 5.47 ± 0.08, 5.83 ± 0.09, 5.57 ± 0.07, 4.05 ± 0.18 and 5.57 ± 0.06 mg/mL, respectively, as determined by the BCA method (*R*^2^ ≥ 0.998). It was noteworthy that the protein concentration of byssus was too low to affect later enzymatic hydrolysis. As shown in [Figure 2](#ijms-19-02100-f002){ref-type="fig"}A,B, there was different protein distribution, i.e., the protein band of 100 kDa in 25 °C water (pH 7.0) was not soluble in 45 °C water (pH 8.5), which probably contributed to the different peptide identification. The effect of enzymatic hydrolysis and the properties of peptides were affected by the solubility of proteins. SDS-PAGE of the enzymatic hydrolysates is shown in [Figure 2](#ijms-19-02100-f002){ref-type="fig"}C, which indicates that the hydrolysis degree of S3 and S6 is much higher than in the other samples.

2.2. Identification of the Peptides in Hydrolysates {#sec2dot2-ijms-19-02100}
---------------------------------------------------

A total of 277 peptides were identified from *M. edulis* by UPLC-Q-TOF-MS; 109, 14, 116, 67, 37, 144, 19, and 36 peptides were identified from S1 to S8, respectively. However, 47 peptides were derived from the hydrolysate of S0. The number of peptides from S1, S3, S4, and S6 was significantly higher than for S0. Over 70% of the peptides from S0 were also identified in all the other tissues separately. All these results indicated that more peptides would be identified if the samples were pretreated by separating the different tissues from *M. edulis* rather than that of the whole part. The number of peptides identified from S6 was the highest among all the samples, and the studies on the adductor muscle were also more extensive in recent years \[[@B18-ijms-19-02100],[@B19-ijms-19-02100],[@B20-ijms-19-02100]\], which indicated that the adductor muscle from *M. edulis* could be a potential source of anticoagulant peptides.

2.3. Activity Prediction and Molecular Docking of Peptides {#sec2dot3-ijms-19-02100}
----------------------------------------------------------

There were 25 peptides that showed higher scores (\>50), listed in [Table 1](#ijms-19-02100-t001){ref-type="table"}. The number of peptides derived from S0 to S8 was 5, 9, 6, 11, 7, 6, 12, 5, and 5, respectively. The results showed that the adductor muscle may contain more bioactive peptides.

The CDCOCKER docking simulation was used to elucidate the molecular mechanisms of interactions between human thrombin and peptides from *M. edulis*. Every peptide has 10 molecular antagonists as docking poses for the docking simulation, as shown in [Figure 3](#ijms-19-02100-f003){ref-type="fig"}A. A peptide named TYS (containing hirudin fragment 54--62) was combined with thrombin and played an important role in inhibiting thrombin. The peptides derived from *M. edulis* proteins may show inhibitory activity against thrombin with a similar mechanism if the peptide and hirudin showed a similar interaction domain with thrombin (TYS). The yellow sphere was defined as the active site and binding site of peptides in [Figure 3](#ijms-19-02100-f003){ref-type="fig"}B. The score of TYS was 170.13. The number of peptides with a higher score (\>170) derived from S0 to S8 was 7, 45, 33, 34, 16, 3, 55, 1, and 3 ([Table 2](#ijms-19-02100-t002){ref-type="table"}), respectively. The percentage of peptides from the adductor muscle was much higher, so the antithrombotic activity of S6 was determined in the following study.

Three peptides, VQQELEDAEERADSAEGSLQK (P1), RMEADIAAMQSDLDDALNGQR (P2), and AAFLLGVNSNDLLK (P3), might be more active due to the higher evaluation levels of activity by both Peptide Ranker and molecular docking. The interaction of antithrombotic peptides with thrombin was shown in [Figure 3](#ijms-19-02100-f003){ref-type="fig"}C. Amino acids combined from the thrombin of P1, P2, and P3 were Lys36-Gln38-Thr74-Arg75-Tyr76-Ile82-Met84, Gln38-Arg67-Thr74-Arg75-Tyr76-Ile82-Met84, and Lys36-Arg67-Thr74, respectively. As is well known, Phe34-Leu65-Arg73-Thr74-Arg75-Tyr76-Glu80-Lys81-Ile82 is the active site 2 in the thrombin molecule \[[@B21-ijms-19-02100]\], and Lys36-Arg73-Arg77-Lys149E in the thrombin molecule works as the binding motif to recognize fibrinogen \[[@B22-ijms-19-02100]\]. The number of combined amino acids from P1--P3 was 5, 4, and 2; their scores were 303.38, 220.49, and 171.47. These results indicated that the more essential amino acids were combined, the higher the score and the stronger the activity \[[@B23-ijms-19-02100]\]. The score of LTQENFDLQHQVQELDGANAGLAK was the highest. However, there were only 5 interactive amino acids involved in the active center of thrombin include, Gln38-Arg73-Thr74-Tyr76-Ile82, which was less than that of P1. Moreover, P1 was derived from the adductor muscle, P2 was derived from the foot and adductor muscle, and P3 was derived from the byssus, pedal retractor muscle, and adductor muscle. Therefore, the adductor muscle may be a potential source for producing peptides with anticoagulant activity.

2.4. Anticoagulant Activity Determination {#sec2dot4-ijms-19-02100}
-----------------------------------------

Anticoagulant activity IC~50~ values of hydrolysate from adductor muscle (0.5\~4 mg/mL) were determined as shown in [Figure 4](#ijms-19-02100-f004){ref-type="fig"}. Results showed that IC~50~ was 1.49 mg/mL according to the fitted equation (y = 2.52 + 39.27x − 4.99x^2^). Moreover, the anticoagulant activity of the samples, foot, byssus, pedal retractor muscle, mantle, gill, and other parts at the same concentration were determined, and the inhibition rate was 43.14 ± 1.29(%), 48.50 ± 0.5(%), 27 ± 2.6(%), 22.55 ± 3.7(%), 19.71 ± 2.8(%), and 24.58 ± 0.81(%), respectively. These results indicated that the hydrolysate from the adductor muscle showed a higher anticoagulant activity than other tissues.

3. Materials and Methods {#sec3-ijms-19-02100}
========================

3.1. Materials and Chemicals {#sec3dot1-ijms-19-02100}
----------------------------

Bicinchonininc acid (BCA) and Cleanert S C18-N solid phase extraction (SPE) column were purchased from Beyotime (Beijing Baoxidi Science & Technology Co., Ltd., Beijing, China); Thrombin (EC 3.4.21.5), formic acid (FA), and acetonitrile (ACN) were purchased from Sigma-Aldrich Co. (St. Louis, MO, USA); Trypsin (EC3.4.21.4, 2.5 × 10^5^ U/g) was purchased from Solarbio (Beijing, China). All other chemicals used in this study were of analytical grade.

3.2. Split of Mytilus edulis Organisms {#sec3dot2-ijms-19-02100}
--------------------------------------

*M. edulis* was manually split into eight parts, i.e., the foot, byssus, pedal retractor muscle, mantle, gill, adductor muscle, viscera, and other parts; these were numbered S1, S2, S3, S4, S5, S6, S7, and S8, respectively, and the Whole *M. edulis* was named S0. The samples were freeze-dried with a vacuum freeze dryer (Ningbo Scientz Biotechnology Co. Ltd., Ningbo, China). The consequent powders were also treated with a ball-milled machine (RETSCH Verder Shanghai Instruments and Equipment Co., Ltd., Shanghai, China), and stored in a dry dish at 4 °C.

3.3. SDS-PAGE {#sec3dot3-ijms-19-02100}
-------------

The protein content of the samples was determined by the Kjeldahl method \[[@B24-ijms-19-02100],[@B25-ijms-19-02100]\]. SDS-PAGE was carried out using AE-8135 (ATTO CORPORATION, Taito-ku, Japan). SDS-PAGE was performed using 10% polyacrylamide resolved gel (pH = 8.8) and 5% stacking gel (pH = 6.8). The protein bands were stained with Coomassie brilliant blue R-250. Premixed Protein Standard (44.3--200 kDa) of Takara Co. Ltd. (Dalian, China) was used for finding the relative molecular weight. The samples were mixed with 10 µL of electrophoretic loading buffer and heated for 5 min in a boiling water bath \[[@B26-ijms-19-02100],[@B27-ijms-19-02100]\]. Different samples were separated by centrifugation at 8000 rpm for 15 min.

3.4. Enzymatic Hydrolysis by Trypsin {#sec3dot4-ijms-19-02100}
------------------------------------

The enzymatic hydrolysis was conducted at 45 °C and pH 8.5. The pH was kept constant at 8.5 using 0.1 M NaOH as a regulator \[[@B1-ijms-19-02100]\]. Once the optimum pH and temperature conditions were achieved, the enzyme trypsin (activity ≥ 5 U/mg) was added \[[@B28-ijms-19-02100],[@B29-ijms-19-02100]\]. After 3 h, trypsin was heated--deactivated at 100 °C for 10 min in a water bath. The leaching effect of the protein from S0 to S8 is demonstrated by SDS-PAGE. The protein concentration was determined by BCA method \[[@B30-ijms-19-02100]\].

3.5. Peptide Identification by UPLC-Q-TOF-MS/MS {#sec3dot5-ijms-19-02100}
-----------------------------------------------

The samples were processed with Cleanert S C18-N Solid phase extraction column \[[@B31-ijms-19-02100]\]. Freeze-dried peptides were dissolved in 0.1% FA (soluble in water) and filtered through a 0.22-μM microporous filter membrane (Millipore, Billerica, MA, USA) before detection by mass spectrometry. Chromatographic separation was carried out at a flow rate of 0.4 mL/min with an injection volume of 15 μL on a C18 column (150 × 3 mm, 3 μm particle size). Peptides were separated using 0.1% FA in ultrapure water (solvent A) and 0.1% FA in ACN (solvent B) at a constant temperature of 25 °C. The gradient elution program was as follows: (i) 0 min 90% A; (ii) 0--2 min 75% A; (iii) 2--10 min 50% A; (iv) 10--20 min 40% A; (v) 20--35 min 60% A; (vi) 35--40 min 90% A \[[@B32-ijms-19-02100],[@B33-ijms-19-02100]\].

Peptides were analyzed using an ESI-MS/MS (Bruker Co. Ltd., Bremen, Germany) with an ion source of ESI coupled with LC system (Thermo Fisher Scientific Co. Ltd., Waltham, MA, USA). The molecular mass and amino acid sequence of the peptides were determined by Mascot searching as follows: (i) The protein database was from the National Center for Biotechnology Information (<https://www.ncbi.nlm.nih.gov/>); (ii) the enzyme was set as trypsin; and (iii) the significance threshold was *p* \< 0.05. The peptides were identified by database matching as well as the manual interpretation of its MS/MS spectrum, and the ion score of 35 was regarded as the identifying threshold \[[@B34-ijms-19-02100]\].

3.6. Activity Prediction by Peptide Ranker {#sec3dot6-ijms-19-02100}
------------------------------------------

The activity of the peptides in samples 0--8 was predicted by the software of Peptide Ranker (<http://bioware.ucd.ie/~compass/biowareweb/Serverpages/peptideranker.php>). Peptide Ranker is a kind of database that provides certain classes of bioactive peptides with specific structural features that endow their particular functions by different classes of peptides. It concluded that there are general shared features of bioactive peptides across different functional classes, indicating that computational prediction may accelerate across many functional classes. The implementation of the predictive method was used to identify among a set of peptides \[[@B35-ijms-19-02100]\]. The peptides with a score of more than 0.5 were considered to be positive results in the present study.

3.7. Molecular Docking {#sec3dot7-ijms-19-02100}
----------------------

Molecular docking of the estimated anticoagulant peptides with thrombin were carried out using Discovery Studio 2017 software (Neotrident Technology Ltd., Beijing, China) according to the method described with some modifications \[[@B18-ijms-19-02100]\]. The structure of peptide was processed and the energy minimized using the steepest descent and conjugate gradient techniques \[[@B36-ijms-19-02100]\]. The corresponding receptor protein was downloaded from the PDB database (<http://www.rcsb.org/pdb/home/home.do>) and also treated by completing the missing amino acids, removing water molecules, and so on \[[@B37-ijms-19-02100]\]. Docking was performed using the CDOCKER docking tool of Discovery Studio software. The best ranked docking pose of peptides in the active site of thrombin was obtained according to the score and binding-energy value \[[@B36-ijms-19-02100]\].

3.8. Determination of Antithrombotic Peptides {#sec3dot8-ijms-19-02100}
---------------------------------------------

A microplate reader was set to a wavelength of 405 nm at 37 °C. The fibrinogen, thrombin, and the samples were all dissolved in 0.05 M Tris-HCl (pH 7.2) containing 0.154 mM sodium chloride. Then, 140 μL of 0.1% fibrinogen solution and 40 μL of samples with different concentrations were added into the plate wells, mixed, and the absorbance of the sample blank was measured. Furthermore, 10 μL of thrombin (12 U/mL) were added and incubated at 37 °C. Finally, the absorbance was measured after 10 min \[[@B36-ijms-19-02100],[@B38-ijms-19-02100],[@B39-ijms-19-02100],[@B40-ijms-19-02100]\]. The control group contained 40 μL of Tris-HCl buffer instead of the sample. The inhibition rate was calculated according to the following Equation (1), where *C*, *Cb*, *S*, and *Sb* represent the absorbance of control, control blank, sample, and sample blank, respectively. $$Inhibitory\ Rate\ (\%) = \frac{(C - Cb) - (S - Sb)}{C - Cb} \times 100\%$$

3.9. Statistical Analysis {#sec3dot9-ijms-19-02100}
-------------------------

Values were expressed as the mean ± SD (*n* ≥ 3). Following the assessment of significant differences between samples by one-way analysis of variance (ANOVA), the level of significance was set at *p* \< 0.05. All statistical tests were conducted using SPSS software 19.0 (SPSS Inc., Chicago, IL, USA).

4. Conclusions {#sec4-ijms-19-02100}
==============

Different peptides components would be produced in the protein hydrolysates of the different tissues from *M. edulis*, which was digested by trypsin. Compared with the sample of blue mussels as a whole, many more peptides can be identified by UPLC-Q-TOF-MS if the tissues are identified separately. The IC~50~ of the hydrolysate from the adductor muscle of *M. edulis* was 1.49 mg/mL. The antithrombotic activity of different hydrolysates of *M. edulis* proteins can probably be attributed to the bioactive peptides in them, such as VQQELEDAEERADSAEGSLQK, RMEADIAAMQSDLDDALNGQR, and AAFLLGVNSNDLLK and so on; these peptides have a relative stronger affinity with thrombin (PDB: 2BVR). The present study may provide new ideas and technology on the screening or identification of peptides with anticoagulant activity on a large scale.

This work was supported by the State Key Research and Development Plan Modern Food Processing and Food Storage and Transportation Technology and Equipment (2017YFD0400201), the National Natural Science Foundation of China (31771926, 31730069).

M.Q. conceived and designed the experiments, performed the experiments, analyzed the data, contributed reagents/materials/analysis tools, wrote the paper, prepared the figures and tables, and reviewed drafts of the paper. M.D. conceived and designed the experiments, analyzed the data, contributed reagents/materials/analysis tools, and reviewed drafts of the paper. M.T., H.C., F.M., and C.Y. have reviewed drafts of the paper.

There is no conflict of interest.

![Eight different parts of *Mytilus edulis* tissues, i.e., foot, byssus, pedal retractor muscle, mantle, gill, adductor muscle, viscera, and other parts, from *Mytilus edulis* were separated and prepared. The protein content of different tissues was measured by the Kjeldahl method. Values are mean ± SD (*n* = 3--6). Different letters beside the bars represent a significant difference between the values.](ijms-19-02100-g001){#ijms-19-02100-f001}

![(**A**) Soluble proteins in 45 °C water at pH 8.5; (**B**) soluble proteins in 25 °C water at pH 7.0 (**C**) proteins and peptides in the enzymatic hydrolysates. S0---Whole tissue; S1---Foot; S2---Byssus; S3---Pedal retractor muscle; S4---Mantle; S5---Gill; S6---Adductor muscle; S7---Viscera; S8---Other parts.](ijms-19-02100-g002){#ijms-19-02100-f002}

![Molecular docking for the interactions of peptide against Thrombin. Molecular structure of thrombin from PDB database (**A**), the yellow sphere showed the docking position; VQQELEDAEERADSAEGSLQK (**B**), RMEADIAAMQSDLDDALNGQR (**C**), AAFLLGVNSNDLLK (**D**), and LTQENFDLQHQVQELDGANAGLAK (**E**). The peptides were marked with yellow sticks; the other sticks are the interactive amino acids of thrombin.](ijms-19-02100-g003){#ijms-19-02100-f003}

![Anticoagulant activity IC50 of enzymatic hydrolysate from adductor muscle. Five different concentrations (0.5\~4 mg/mL) were investigated, as measured by a microplate reader.](ijms-19-02100-g004){#ijms-19-02100-f004}

ijms-19-02100-t001_Table 1

###### 

Peptides released from *Mytilus edulis* proteins hydrolyzed by trypsin.

  Sequence                    Length of Peptide   Molecular Weight   Tissues                              Peptide Ranker
  --------------------------- ------------------- ------------------ ------------------------------------ ----------------
  GPAGIIGLIGPK                12                  857.4555           S1, S2, S3                           0.83
  GPIGPAGGKGPTGPK             15                  1289.7138          S2                                   0.83
  NDFDKDFFK                   9                   1174.5336          S6                                   0.78
  AGLQFPVGR                   9                   569.3174           S0, S3, S4, S5, S6, S7, S8           0.76
  GYSAELFR                    8                   792.3822           S1                                   0.71
  SPNFTKPGK                   9                   801.4345           S1                                   0.7
  GPTGPQGLR                   9                   881.4739           S1, S2                               0.68
  FPGQLNADLR                  10                  1129.5894          S3, S5                               0.67
  LAVNMVPFPR                  10                  1029.5439          S0, S3, S4, S5, S6, S7, S8           0.67
  SYSAELFR                    8                   971.4715           S3, S4, S6                           0.65
  TATSPFFK                    8                   897.4602           S3, S4, S7, S8                       0.65
  KLAVNMVPFPR                 11                  1270.7253          S0                                   0.64
  AVFPSIVGRPR                 11                  1197.7004          S0, S1, S2, S3, S4, S5, S6, S7, S8   0.62
  LSHYAFSSLR                  10                  1180.4689          S5                                   0.62
  AAFLLGVNSNDLLK              14                  1473.8192          S3, S6                               0.59
  GIQGPEGELGPVGK              14                  1337.7210          S2                                   0.58
  TLYGFGG                     7                   713.3405           S5                                   0.58
  WSYAPQSR                    8                   993.4698           S1, S3, S4, S6                       0.58
  VQQELEDAEERADSAEGSLQK       21                  2331.0806          S6                                   0.57
  AGFAGDDAPR                  10                  975.4435           S1, S2, S3, S4, S6, S7, S8           0.56
  SFVNDIFER                   9                   824.5024           S0                                   0.56
  NLNADVDSVRESLEEEQESKSDLQR   25                  2889.364           S1                                   0.55
  SPNFGRPGNASK                12                  1230.6178          S3, S6                               0.55
  ALAADINLR                   9                   956.5409           S6                                   0.53
  RMEADIAAMQSDLDDALNGQR       21                  2319.064           S1, S6                               0.5

Note: S0---Whole tissue; S1---Foot; S2---Byssus; S3---Pedal retractor muscle; S4---Mantle; S5---Gill; S6---Adductor muscle; S7---Viscera; S8---Other parts. Peptides with a score greater than 0.5 were considered to be positive results in the present study.

ijms-19-02100-t002_Table 2

###### 

Molecular docking of predicted antithrombotic peptides.

  Peptide                    Length of Peptide   Tissue(s)                       -CDOCKERENERGY
  -------------------------- ------------------- ------------------------------- ----------------
  LTQENFDLQHQVQELDGANAGLAK   24                  S1                              311.73
  VQQELEDAEERADSAEGSLQK      21                  S6                              303.38
  TLADLQKEEDKVNHLNK          17                  S1                              282.78
  MEKENALDRAEQLEQK           16                  S1                              272.87
  KKLEQDINELEMALDTSNR        19                  S1                              270.74
  SIQTENDLDNTQTQLQDVQAK      21                  S6                              264.94
  AKLESTLDEMEDNLER           16                  S1                              255.701
  ITIQQELEDARSLLEHAER        19                  S1, S2, S3, S6                  254.26
  LADELRQEQDNYKNAESLR        19                  S6                              251.11
  KLEQDINELEMALDTSNR         18                  S1                              249.98
  HQEALNDLTDQLEHMGK          17                  S1, S2, S3, S4, S6              241.79
  RRHQEALNDLTDQLEHMGK        20                  S1, S6                          238.67
  NRLQGELDDLLIEVER           16                  S1                              237.02
  VKELQTEIDTAHTEAR           16                  S1                              236.54
  DLEETTLQHEAQVSSLR          17                  S6                              236.102
  MIEEAEDVASITMNKYR          17                  S1, S6                          235.72
  RHQEALNDLTDQLEHMGK         18                  S1, S2, S3, S4 S6               232.22
  WIAEEADKKYEEAAR            15                  S1, S2, S3, S6                  231.80
  AAVLEYLAAEVLELAGNAAR       20                  S0                              231.28
  LLDEEDAASELEGLKK           16                  S1                              230.16
  NQLIIEIDSLQAMNDGLQK        19                  S2, S3, S6                      228.63
  LADELRQEQDNYK              13                  S2, S3, S6                      227.66
  QNLQVQLAAIQSDYDNLNAR       20                  S6                              227.36
  VIDLEEQLTVVGANIK           16                  S1, S6                          226.86
  NLAEEIHELTEQLSEGGR         18                  S6                              226.02
  AAEERADRLQAEVNR            15                  S2, S3, S6                      225.98
  IRELEDSLDSEREMR            15                  S1, S4                          225.89
  IRDLENELEADQRR             14                  S2, S3, S4, S6                  225.40
  MIEEAEDVASITMNK            15                  S6                              223.61
  ELEDSLDSEREMR              13                  S2, S3, S6                      222.18
  RMEADIAAMQSDLDDALNGQR      21                  S1, S6                          220.49
  ENALDRAEQLEQK              13                  S1, S6                          220.44
  EVDRLEDELLTEK              13                  S6                              219.35
  EITVRLEEAEAFAQR            15                  S6                              217.95
  TFDREGQGYISGAEMR           16                  S1                              217.67
  KLAITEVDLERAEAR            15                  S1                              214.16
  ATQEVVEELEGVKR             14                  S1, S2, S3                      213.487
  LTEVQLQVTALTNDKR           16                  S2, S3, S6                      213.42
  LQGELDDLLIEVER             14                  S1                              213.06
  AVFVDLEPTVVDEVR            15                  S5                              212.988
  VQFNLKDYQSSANVKHAVDK       20                  S4                              212.98
  IRDLENELEADQR              13                  S1, S2, S3, S4, S6              212.26
  HQGVMVGMGQKDSYVGDEAQSKR    23                  S1                              212.01
  ELQTEIDTAHTEAR             14                  S1                              211.61
  LEDAMGTSTTVSEVSR           16                  S6                              211.59
  TLQGEMAQQDEQISK            15                  S1                              211.51
  IAIIITDGKPTDINATQR         18                  S2, S3, S4                      211.34
  SGVLVRPK                   8                   S0, S8                          210.81
  MSADSKIDALEGSNSR           16                  S1, S2, S3, S6                  209.52
  DLENELEADQRR               12                  S2, S3, S6                      209.289
  AQYEETSDTIEALRR            15                  S1                              209.038
  DLYANTVLSGGTTMFPGIADR      21                  S6                              207.485
  QLDDTRNQLSVSER             14                  S6                              206.48
  LTGELEDLGIDVER             14                  S6                              206.25
  QIAEHEQEIQSLTR             14                  S6                              205.14
  ELDDVQSQLSHSMK             14                  S1                              204.91
  QLEDAEHTIGSLTK             14                  S1                              204.72
  ELEGELDSEQRR               12                  S6                              203.33
  LAEAEQAAEAANAK             14                  S1                              202.27
  IRELEDSLDSER               12                  S2, S3, S4                      202.17
  ALDSMQASLEAEAK             14                  S2, S3, S6                      202.096
  QVAELTSITDQLTMK            15                  S6                              201.63
  INELAAQVSSAQAQKR           16                  S1                              201.27
  DKSALTSQLEEAKR             14                  S1                              201.151
  KNAENELGEVTVR              13                  S0, S2, S3, S4, S6              200.88
  LLSGVTIAQGGVLPNIQAVLLPK    23                  S0                              200.55
  AKIEDDYNSLQK               12                  S1, S6                          198.5
  SYYDTSREENDIRR             14                  S6                              197.19
  SYELPDGQVITIGNER           16                  S0,S1, S2, S3, S4, S6, S7, S8   196.76
  VTDLQSELENAQK              13                  S2, S3, S6                      196.65
  DLENELEADQR                11                  S6                              196.13
  LDLAGRDLTDYLMK             14                  S1, S2, S3, S4, S6              191.19
  KVGINYQPPTVVPGGDLAK        19                  S0                              190.22
  DIEDLETTLAK                11                  S1                              189.759
  SALYEDTFIPEVIRPR           16                  S2, S3, S6                      188.36
  LEDDQSLIAQLQR              13                  S6                              188.31
  YEEESENASSLR               12                  S2, S3, S4, S6                  188.24
  MSATFIGNSTAIQELFKR         18                  S5                              184.40
  NAENELGEVTVR               12                  S6                              183.23
  AMSIMNSFVNDIFER            15                  S0, S2, S3, S4, S5, S8          178.809
  DSYVGDEAQSKR               12                  S1, S2, S3, S4                  177.848
  SALTSQLEEAKR               12                  S1                              177.63
  DSYVGDEAQSK                11                  S1, S2, S3                      177.572
  KRITIQQELEDAR              13                  S2, S3, S6                      177.35
  KAQSLIDEAEQR               12                  S2, S3, S4                      177.22
  AQSLIDEAEQR                11                  S4                              176.453
  ETVQASDEDRR                11                  S6                              176.32
  QLENENAALQK                11                  S2, S3                          175.83
  KMEGENSEMKR                11                  S1                              174.67
  QEYDESGPSIVHR              13                  S6                              174.00
  LTDEQVDDIIR                11                  S6                              173.52
  ATQEAVEDLER                11                  S2, S3                          173.43
  KLAITEVDLER                11                  S6                              173.15
  SKLQSEVTEINR               12                  S1                              172.71
  ELEDSLDSER                 12                  S3, S6                          172.60
  ITIQQELEDAR                11                  S2, S3, S6                      171.94
  LTDMIDKLQSK                11                  S1                              171.79
  AAFLLGVNSNDLLK             14                  S2, S3, S6                      171.476
  SLENTIAELQHK               12                  S2, S3, S6                      170.94
  ENKNLADEIR                 12                  S1                              170.32

Note: S0---Whole tissue; S1---Foot; S2---Byssus; S3---Pedal retractor muscle; S4---Mantle; S5---Gill; S6---Adductor muscle; S7---Viscera; S8---Other parts. Peptides with scores greater than 170 were considered to be anticoagulant peptides in the present study.
